Compare Capri Holdings Ltd (CPRI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Eli Lilly And Co — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while Eli Lilly And Co trades at $1,164.15 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 622.8× Capri Holdings Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Eli Lilly And Co for 93 Days on average.
| CPRI | LLY | |
|---|---|---|
Market Cap | $1.67B | $1.04T |
Volume | 3,722,279 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $1.28K |
52-Week Low | $12.71 | $799.57 |
Typical Hold Time | 41 Days | 93 Days |
Enterprise Value | $2.95B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $1.18 billion in 2025, though recent quarters have consistently beaten EPS estimates. Revenue has declined from $5.7 billion in 2022 to $4.44 billion in 2025, but management expects second-half growth driven by brand revitalization efforts at Michael Kors and Jimmy Choo.
The stock presents a mixed outlook with a low P/S ratio of 0.5 and a consensus price target of $20.57 offering potential upside. However, significant risks include persistent revenue declines, high debt levels, and competitive pressures in the luxury sector. Analyst sentiment is divided with 44% buy ratings versus 52% hold, reflecting uncertainty about the turnaround timeline.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
